Trial Profile
Ability of belimumab in achieving low disease activity states in patients with systemic lupus erythematosus: A prospective observational study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism